Glucosamine ± chondroitin

Glucosamine is an amino sugar used to build cartilage glycosaminoglycans; chondroitin sulfate is itself a major cartilage glycosaminoglycan. Substrate provision is the pitch. Whether oral dosing raises joint concentrations enough to matter is contested — which is why this entry lives and dies on the clinical trials. And the trials disagree in an unusually clean pattern.

The positive trials — and who funded them

Two 3-year placebo-controlled RCTs of crystalline glucosamine sulfate 1500 mg once daily found essentially no joint-space narrowing on treatment versus roughly 0.3 mm of loss on placebo, plus modest symptom benefit: Reginster 2001 (n=212) and its replication Pavelka 2002 (n=202). These are the only supplement trials anywhere claiming structural protection of cartilage.

Both were funded by Rottapharm, the manufacturer of the prescription-grade product tested, with company-affiliated authors. And radiographic joint-space width — the entire basis of the structure claim — is sensitive to knee positioning, with debated per-millimeter clinical meaning.

The null trials — and who funded those

The NIH-funded GAIT trial (n=1583, 24 weeks) found glucosamine HCl, chondroitin, and their combination all indistinguishable from placebo on the primary endpoint: 60.1% of placebo patients responded versus 64–66.6% on the supplements. The frequently quoted combination benefit in moderate-to-severe pain was a post-hoc subgroup, never confirmed prospectively. The 2-year GAIT continuation stayed null — no arm, including celecoxib, beat placebo. An investigator-initiated Spanish trial of the combination was stopped for futility with placebo numerically ahead on pain.

The meta-analytic view matches. The BMJ network meta-analysis of large trials (n=3803) put pooled pain effects at 0.3–0.5 cm on a 10 cm scale — below its 0.9 cm clinical-relevance threshold — with minimal joint-space effects, and found industry-funded trials produced systematically larger effects. The OA Trial Bank individual-patient-data analysis (n=1625) found no effect and no responsive subgroup — though manufacturer-held datasets from the positive sulfate trials were not contributed.

The industry-funded MOVES trial found the combination non-inferior to celecoxib at 6 months, but with no placebo arm both results could be regression to the mean.

Formulation is the fault line

The mixed results split cleanly by salt. The positive trials used European crystalline glucosamine sulfate, 1500 mg once daily (not divided), for 6 months to 3 years. US supplements are typically glucosamine HCl — the salt that failed in GAIT — and supplement-grade chondroitin has documented content-quality variability. Most retail SKUs bundle HCl salt, low-grade chondroitin, and MSM in a combination matching no trialed regimen. If you use this at all, the only formulation with positive (if conflicted) data is crystalline glucosamine sulfate, and nothing is expected before 4–12 weeks.

Where the guidelines landed

OARSI's 2019 guideline recommends against glucosamine and chondroitin for knee OA, citing low-quality, conflicting evidence; AAOS and ACR guidance is similarly negative. European bodies (ESCEO) endorse prescription-grade crystalline glucosamine sulfate specifically — via a committee with documented manufacturer ties, which readers deserve to know.

What I take from it

The contradiction is the story: every large trial free of manufacturer involvement is null, and every positive structure trial was funded by the product's manufacturer. After more than two decades, no independent group has tried to replicate the crystalline-sulfate findings — itself informative. Safety, at least, is genuinely strong: adverse-event rates matched placebo across 3-year exposures, with the usual cautions for shellfish allergy, glucose monitoring in diabetes, and case reports of chondroitin interacting with warfarin.